Phase 1b/2a Program Commences for RVX-208

Calgary, Canada (ots/PRNewswire) - Resverlogix Corp.
("Resverlogix" or the "Company") (TSX: RVX) is pleased to announce
that the Phase 1b/2a program for the study of RVX-208 in subjects
with normal lipids and those with low high-density lipoprotein (HDL)
cholesterol has proceeded according to plan.

"We are very excited about moving forward into this important
28-day study with RVX-208. Our previous clinical study demonstrated
that RVX-208 was safe, tolerable and had favourable
pharmacokinetics," stated Dr. Allan Gordon, Senior Vice President
Clinical Development of Resverlogix. "This trial will continue to
examine safety and tolerance as well it is a proof of principle study
for ApoA-I production and HDL functionality. Approximately half of
the subjects will have low levels of HDL cholesterol, a condition
associated with significant increased risk of cardiovascular
disease," added Dr. Gordon.

"The ensuing Phase 1b/2a study comprises several novel facets to
expedite the clinical process for RVX-208 and its eventual
registration as a drug," stated Donald J. McCaffrey, President and
CEO of Resverlogix. McCaffrey further confirmed, "Along with the
required regulatory provisions that must be addressed such as safety,
tolerance and pharmacokinetics, the study also will measure key
reverse cholesterol transport markers which RVX-208 impacts. These
are exclusive favourable features that make this drug unique among
its competitors."

RVX-208, a novel small molecule therapeutic that facilitates
endogenous ApoA-I production, is positioned to be one of the most
promising emerging drugs in the treatment of atherosclerosis. To the
Company's knowledge RVX-208 is the only novel small molecule that is
specifically designed to increase ApoA-I production and thereby raise
HDL levels thus enhancing HDL functionality to augment reverse
cholesterol transport.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet needs. The NexVas(TM) program is the
Company's primary focus which is to develop novel small molecules
that enhance ApoA-I. These vital therapies address the grievous
burden of atherosclerosis and other important diseases such as acute
coronary syndrome, diabetes, Alzheimer's disease and other vascular
disorders. The Company's secondary focus is TGF-Beta Shield(TM), a
program that aims to address burgeoning grievous diseases, such as
cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock
Exchange (TSX:RVX). For further information please visit
http://www.resverlogix.com.

This news release may contain certain forward-looking statements
that reflect the current views and/or expectations of Resverlogix
Corp. with respect to its performance, business and future events.
Such statements are subject to a number of risks, uncertainties and
assumptions. Actual results and events may vary significantly. The
TSX Exchange does not accept responsibility for the adequacy or
accuracy of this news release.

Website: http://www.resverlogix.com

For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Email:
Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor
Relations, Resverlogix Corp., Phone: +1-403-254-9252, Email:
Sarah@resverlogix.com

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-604-538-7072, Email:
Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor
Relations, Resverlogix Corp., Phone: +1-403-254-9252, Email:
Sarah@resverlogix.com